Positive News SentimentPositive NewsNASDAQ:OTLK Oncobiologics (OTLK) Stock Price, News & Analysis $1.60 -0.15 (-8.57%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.66 +0.05 (+3.44%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncobiologics Stock (NASDAQ:OTLK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncobiologics alerts:Sign Up Key Stats Today's Range$1.60▼$1.8050-Day Range$1.41▼$2.0352-Week Range$0.87▼$9.25Volume2.90 million shsAverage Volume818,359 shsMarket Capitalization$53.71 millionP/E RatioN/ADividend YieldN/APrice Target$9.60Consensus RatingModerate Buy Company OverviewOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More… Oncobiologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreOTLK MarketRank™: Oncobiologics scored higher than 48% of companies evaluated by MarketBeat, and ranked 608th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncobiologics has only been the subject of 2 research reports in the past 90 days.Read more about Oncobiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncobiologics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncobiologics is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncobiologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.91% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncobiologics does not currently pay a dividend.Dividend GrowthOncobiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.91% of the float of Oncobiologics has been sold short.Short Interest Ratio / Days to CoverOncobiologics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentOncobiologics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oncobiologics this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows1 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncobiologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Oncobiologics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Oncobiologics is held by institutions.Read more about Oncobiologics' insider trading history. Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Stock News HeadlinesOutlook Therapeutics to Participate in a Virtual Investor Lunch Break EventJune 18, 2025 | globenewswire.comCFA Institute 2025 Graduate Outlook Survey: Finance Top Career ChoiceJune 12, 2025 | tmcnet.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.June 30 at 2:00 AM | Paradigm Press (Ad)Steve Wilks Pleased With Jets Defensive OutlookJune 12, 2025 | msn.comOutlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | finanznachrichten.deOutlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDJune 10, 2025 | globenewswire.comOilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 MomentJune 7, 2025 | msn.comChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New PricingJune 7, 2025 | techrepublic.comTSee More Headlines OTLK Stock Analysis - Frequently Asked Questions How have OTLK shares performed this year? Oncobiologics' stock was trading at $1.89 at the beginning of 2025. Since then, OTLK shares have decreased by 15.3% and is now trading at $1.60. View the best growth stocks for 2025 here. How were Oncobiologics' earnings last quarter? Oncobiologics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.15. When did Oncobiologics' stock split? Oncobiologics's stock reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Oncobiologics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/15/2025Today6/29/2025Next Earnings (Estimated)8/13/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OTLK CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$9.60 High Stock Price Target$21.00 Low Stock Price Target$3.00 Potential Upside/Downside+500.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.37 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-271.12% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.09) per share Price / Book-0.52Miscellaneous Outstanding Shares33,570,000Free Float31,957,000Market Cap$53.71 million OptionableOptionable Beta0.31 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:OTLK) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.